Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?
Cavalier, Etienne ; LUKAS, Pierre ; BEKAERT, Anne-Catherine et al
in Clinical Chemistry & Laboratory Medicine (in press)
BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated ... [more ▼]
BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated immunoassays and against a VDSP-traceable liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in six different populations. We also supplemented 40 healthy volunteers with either 600,000 IU of vitamin D2 or 100,000 of vitamin D3 to evaluate the performance of the immunoassays vs. the LC-MS/MS. METHODS: Precision and limit of quantification were assessed, 25(OH)D2 and C3-epimer recovery were calculated. Two hundred and forty samples obtained in healthy Caucasians and Africans, osteoporotic, hemodialyzed and intensive care patients and 3rd trimester pregnant women were analyzed by all methods. Correlation was studied using Passing-Bablok and Bland-Altman analysis. Concordance correlation coefficient (CCC) was calculated to evaluate agreement between immunoassays and LC-MS/MS. We verified if patients were homogeneously classified with the immunoassays when they took vitamin D2 or vitamin D3 after 1, 7 and 28 days. RESULTS: We observed excellent analytical features and showed a very good correlation to the LC-MS/MS results in the overall population. Compared to the other immunoassays, concordance of the new Abbott assay with the LC-MS/MS was at least similar, and often better in diseased populations. Althought the cross-reactivity with 25(OH)D2 was not of 100%, there was no significant difference in the classifications of the patients, either supplemented with D2 or D3 or after 7 or 28 days. CONCLUSIONS: This modified version of the Abbott Architect assay is clearly improved compared to the previous one and presents a better agreement with the LC-MS/MS. [less ▲]Detailed reference viewed: 21 (7 ULg)
Vitamin K plasma levels determination in human health
; ; et al
in Clinical Chemistry & Laboratory Medicine (in press)Detailed reference viewed: 14 (2 ULg)
Fibroblast growth factor 23 in acute burn patients: Novel insights from an intact-form assay.
ROUSSEAU, Anne-Françoise ; ; DELANAYE, Pierre et al
in Burns : Journal of the International Society for Burn Injuries (in press)
INTRODUCTION: Fibroblast growth factor 23 (FGF23) is a key regulator in phosphate and vitamin D metabolism When measured with c-terminal assay, it has been shown to be increased following burn. Progress ... [more ▼]
INTRODUCTION: Fibroblast growth factor 23 (FGF23) is a key regulator in phosphate and vitamin D metabolism When measured with c-terminal assay, it has been shown to be increased following burn. Progress in understanding FGF23 physiology has emphasized the importance of assessing the intact form of FGF23. METHODS: The present cohort study is a complementary analysis of a previously published work. Patients >18 years, admitted within 24h after injury with burn surface area (BSA) >10% were included. C-terminal (c-term) and intact (i) FGF23 assay were performed at admission and every week during 4 weeks of follow-up. Inflammation and iron status were assessed at the same time points. RESULTS: Twenty patients were initially included and 12 were followed until day 28. The c-term FGF23 tended to gradually increase during the 4 weeks of follow-up while iFGF23 was quite stable into normal ranges. Iron status showed a typical inflammatory profile. C-term FGF23 was significantly positively correlated with c-reactive protein (CRP) and negatively correlated with iron levels. iFGF23 was not correlated with CRP or iron. CONCLUSION: FGF23 status following burn is characterized by a dissociation between c-term FGF23 and iFGF23. The hypothesis of an increased cleavage may be raised. Respective role of inflammation and iron levels in such deregulation need to be specified. Both c-term and intact assays should be performed in further studies aiming to increase knowledge on FGF23 regulation and effects in burn patients. [less ▲]Detailed reference viewed: 31 (2 ULg)
Mesure de la force de préhension chez le patient hémodialysé : quand l’effectuer ?
QUINONEZ, Kevin ; Buckinx, Fanny ; KRZESINSKI, Jean-Marie et al
Conference (2017, March 18)Detailed reference viewed: 15 (3 ULg)
Glomerular filtration rate in healthy living potential kidney donors: a meta-analysis supporting the construction of the the Full Age Spectrum equation.
; ; et al
in Nephron (2017), 135(2), 105-119Detailed reference viewed: 26 (1 ULg)
Discrepancies between the Cockcroft–Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies
DELANAYE, Pierre ; ; SCHEEN, André et al
in Clinical Pharmacokinetics (2017), 56(2), 193-205Detailed reference viewed: 42 (3 ULg)
The added value of plasma or urinary NGAL concentrations in clinical practice
Gregoire, Emilien ; ; GUIOT, Julien et al
Poster (2017, January 13)Detailed reference viewed: 40 (4 ULg)
The closure of arteriovenous fistula in kidney transplant recipients is associated with an acceleration of kidney function decline
WEEKERS, Laurent ; VANDERWECKENE, Pauline ; et al
in Nephrology Dialysis Transplantation (2017)
ABSTRACT Background. The creation of arteriovenous fistula (AVF) may retard chronic kidney disease progression in the general population. Conversely, the impact of AVF closure on renal function in kidney ... [more ▼]
ABSTRACT Background. The creation of arteriovenous fistula (AVF) may retard chronic kidney disease progression in the general population. Conversely, the impact of AVF closure on renal function in kidney transplant recipients (KTRs) remains unknown. Methods. From 2007 to 2013, we retrospectively categorized 285 KTRs into three groups: no AVF (Group 0, n = 90), closed AVF (Group 1, n = 114) and left-open AVF (Group 2, n = 81). AVF closure occurred at 653 ± 441 days after kidney transplantation (KTx), with a thrombosis:ligation ratio of 19:95. Estimated glomerular filtration rate (eGFR) was determined using the Modification of Diet in Renal Disease equation. Linear mixed models calculated the slope and intercept of eGFR decline versus time, starting at 3 months post-KTx, with a median follow-up of 1807 days (95% confidence interval 1665–2028). Results. The eGFR slope was less in Group 1 (−0.081 mL/min/ month) compared with Group 0 (−0.183 mL/min/month; P = 0.03) or Group 2 (−0.164 mL/min/month; P = 0.09). Still, the eGFR slope significantly deteriorated after (−0.159 mL/min/month) versus before (0.038 mL/min/month) AVF closure (P= 0.03). Study periods before versus after AVF closure were balanced to a mean of 13.5 and 12.5 months, respectively, with at least 10 observations per patient (n = 99). Conclusions. In conclusion, a significant acceleration of eGFR decline is observed over the 12 months following the closure of a functioning AVF in KTRs. [less ▲]Detailed reference viewed: 37 (12 ULg)
The global burden of chronic kidney disease: estimates, variability and pitfalls.
; ; DELANAYE, Pierre
in Nature Reviews Nephrology (2017), 13(2), 104-114Detailed reference viewed: 15 (0 ULg)
Association entre taux circulants de matrix-gla protéine et rigidité artérielle en transplantation rénale.
; ; DELANAYE, Pierre et al
Conference (2016, December)Detailed reference viewed: 18 (6 ULg)
The closure of arteriovenous fistula is associated with a significant acceleration of eGFR decline in kidney transplant recipients
Jouret, François ; DELANAYE, Pierre ; VANDERWECKENE, Pauline et al
Poster (2016, November)
Background The creation of arteriovenous fistula (AVF) may retard chronic kidney disease progression in the general population. Conversely, there is limited literature regarding the impact of AVF closure ... [more ▼]
Background The creation of arteriovenous fistula (AVF) may retard chronic kidney disease progression in the general population. Conversely, there is limited literature regarding the impact of AVF closure on renal function in kidney transplant recipients (KTR). Methods All KTR were retrospectively identified from 01/01/2007 to 31/12/2013, and grouped into: (0) no AVF; (1) closed AVF; and (2) left open AVF. Glomerular filtration rate was estimated (eGFR) upon MDRD and FAS equations. Linear mixed models calculated the slope and intercept of eGFR decline versus time, starting at 3 months post transplantation (Tx). Comparative analyses of eGFR slopes were performed among groups, as well as before vs after AVF closure in group 1. For the latter, time was balanced before vs after AVF closure, with at least 10 observations per patient. Results The cohort included 285 KTR (Table 1), with a median follow-up of 1750 days [1665; 2028]. Focusing on group 1, AVF closure occurred after a mean time of 653 ± 441 days post Tx, with a thrombosis/ligation ratio of 19/95. Balanced study periods before vs after AVF closure lasted 15.7 and 14.9 months, respectively. No difference was found between corresponding intercepts (p, 0.11). By contrast, eGFR slopes were significantly different before (0.043 ml/min/year) versus after (-0.176 ml/min/year) AVF closure (p, 0.0115). Similar observations were obtained using FAS equation Conclusion A significant acceleration of eGFR decline is observed over the 15 months following the closure of functioning AVF in KTR. [less ▲]Detailed reference viewed: 36 (4 ULg)
Comparisons of estimated GFR and Cockcroft Gault equations: calibration against relative risk for all-cause mortality.
; ; DELANAYE, Pierre et al
Poster (2016, November)Detailed reference viewed: 12 (2 ULg)
Glomerular filtration rate in healthy living potential kidney donors: a meta-analysis.
; ; DELANAYE, Pierre
Poster (2016, November)Detailed reference viewed: 11 (2 ULg)
Large variations between four methods for sclerotin determination in patients undergoing GFR measurement and in hemodialyzed patients before and after a single dialysis session.
CAVALIER, Etienne ; DELANAYE, Pierre
Poster (2016, November)Detailed reference viewed: 8 (1 ULg)
Weak performance of glomerular filtration rate equations in stable lung/liver transplant recipients compared to 51Cr-EDTA clearance.
; ; et al
Conference (2016, November)Detailed reference viewed: 10 (2 ULg)
Measurement of glomerular filtration rate by plasma iohexol clearance: single versus multiple samples method.
DELANAYE, Pierre ; CAVALIER, Etienne
Poster (2016, November)Detailed reference viewed: 9 (1 ULg)
Is there a place for BTR markers in renal osteodystrophy?
Conference (2016, October 15)Detailed reference viewed: 22 (1 ULg)
Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1 : How to measure glomerular filtration rate with iohexol?
DELANAYE, Pierre ; ; et al
in Clinical Kidney Journal (2016)
While there is general agreement on the necessity tomeasure glomerular filtration rate (GFR) inmany clinical situations, there is less agreement on the bestmethod to achieve this purpose. As the gold ... [more ▼]
While there is general agreement on the necessity tomeasure glomerular filtration rate (GFR) inmany clinical situations, there is less agreement on the bestmethod to achieve this purpose. As the gold standardmethod for GFR determination, urinary (or renal) clearance of inulin, fades into the background due to inconvenience and high cost, a diversity of filtrationmarkers and protocols compete to replace it. In this review, we suggest that iohexol, a non-ionic contrast agent, is most suited to replace inulin as the marker of choice for GFR determination. Iohexol comes very close to fulfilling all requirements for an ideal GFRmarker in terms of low extra-renal excretion, low protein binding and in being neither secreted nor reabsorbed by the kidney. In addition, iohexol is virtually non-toxic and carries a low cost. As iohexol is stable in plasma, administration and sample analysis can be separated in both space and time, allowing access to GFR determination across different settings. An external proficiency programme operated by Equalis AB, Sweden, exists for iohexol, facilitating interlaboratory comparison of results. Plasma clearance measurement is the protocol of choice as it combines a reliable GFR determination with convenience for the patient. Single-sample protocols dominate, butmultiple-sample protocolsmay bemore accurate in specific situations. In lowGFRs one ormore late samples should be included to improve accuracy. In patients with large oedema or ascites, urinary clearance protocols should be employed. In conclusion, plasma clearance of iohexol may well be the best candidate for a common GFR determination method. [less ▲]Detailed reference viewed: 28 (7 ULg)